| Strain Name |
C57BL/6-Pdcd1tm1(PDCD1)Bcgen Cd274tm1(CD274)Bcgen Sirpatm1(SIRPA)Bcgen Cd47tm1(CD47)Bcgen/Bcgen |
Common Name | B-hPD-1/hPD-L1/hSIRPA/hCD47 mice |
| Background | C57BL/6 | Catalog number | 140577 |
|
Aliases |
CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, Hsle1, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1, B7DC, Btdc, CD273, PD-L2, PDCD1L2, PDL2, bA574F11.2,BIT, CD172A, MFR, MYD-1, P84, PTPNS1, SHPS1, SIRP, IAP, MER6, OA3 |
||
|
NCBI Gene ID |
18566,60533,19261,16423 | ||
Protein expression analysis
Antitumor activity of anti-human PD-1 antibody pembrolizumab (in house) combined with anti-human CD47 antibody Hu5F9 (in house) in B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. (A) Pembrolizumab combined with Hu5F9 inhibited MC38-hPD-L1/hCD47 tumor growth in B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. Murine colon cells (5E5) were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice (female, 8week-old, n=5). Mice were grouped when tumor volume reached approximately 150 mm3, at which time they were treated with antibodies with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of pembrolizumab and Hu5F9 shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hPD-L1/hSIRPA/hCD47 mice provide a powerful preclinical model for in vivo evaluation of combination therapy of anti-human PD-1 and anti-human CD47 antibodies. Values are expressed as mean ± SEM.
Antitumor activity of anti-human PD-L1 antibody Atezolizumab (in house) combined with anti-human CD47 antibody Hu5F9 (in house) in B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. (A) Atezolizumab combined with Hu5F9 inhibited MC38-hPD-L1/hCD47 tumor growth in B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. Murine colon cells (5E5) were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice (female, 8week-old, n=5). Mice were grouped when tumor volume reached approximately 150 mm3, at which time they were treated with antibodies with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of Atezolizumab and Hu5F9 shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hPD-L1/hSIRPA/hCD47 mice provide a powerful preclinical model for in vivo evaluation of combination therapy of anti-human PD-L1 and anti-human CD47 antibodies. Values are expressed as mean ± SEM.
Antitumor activity of anti-human PD-1 antibody combined with anti-human CD47 antibody in B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. (A) Anti-human PD-1 antibody combined with anti-human CD47 antibody inhibited MC38-hPD-L1/hCD47 tumor growth in B-hPD-1/hPD-L1/hSIRPA/hCD47 mice. Murine colon cells (2E5) were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hSIRPA/hCD47 mice (female, 6-8 week-old, n=8). Mice were grouped when tumor volume reached 50-80 mm3, at which time they were treated with antibodies with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, combination of anti-PD-1 and anti-CD47 shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hPD-L1/hSIRPA/hCD47 mice provide a powerful preclinical model for in vivo evaluation of combination therapy of anti-human PD-1 and anti-human CD47 antibodies. Values are expressed as mean ± SEM. PD-1 Ab and CD47 Ab are both provided by the clients)
+86-10-56967680
info@bbctg.com.cn